ETF Building Blocks Content Hub Steady Rate Cuts Feed Surging Biotech ETF SBIO By Nick Peters-GoldenNovember 13, 2024
ETF Building Blocks Content Hub How Election Results Could Impact Biotech ETFs By Todd ShriberNovember 12, 2024
ETF Building Blocks Content Hub Biotech ETF SBIO Laps Tech Rivals Over 1 Year By Nick Peters-GoldenOctober 22, 2024
ETF Building Blocks Content Hub Tailwinds Emerging for This Biotech ETF By Todd ShriberSeptember 27, 2024
ETF Building Blocks Content Hub Biotech Stocks Are Perking Up. This ETF Is Responding By Todd ShriberSeptember 4, 2024
ETF Building Blocks Content Hub Biotech ETF SBIO Rides Strong Momentum Into Rate Cuts By Nick Peters-GoldenAugust 29, 2024
Disruptive Technology Content Hub Disruptive Theme of the Week: Themes for a Lower Rate Environment By Jane EdmondsonAugust 22, 2024
ETF Building Blocks Content Hub Positive Biotech M&A Activity in 1H Boosts Case for Biotech ETF SBIO By Nick Peters-GoldenAugust 19, 2024
ETF Building Blocks Content Hub Returns Spiking for This Rate-Sensitive ETF By Nick Peters-GoldenJuly 19, 2024
ETF Building Blocks Content Hub Patent Cliffs Could Spark Wave of Biotech M&A By Todd ShriberJuly 18, 2024
ETF Building Blocks Content Hub Big Pharma Has the Firepower for Biotech Deal-Making By Todd ShriberJune 14, 2024
ETF Building Blocks Content Hub Biopharma R&D Trends Could Bode Well for This ETF By Todd ShriberMay 7, 2024
ETF Building Blocks Content Hub There Could Be Signs of Life for Biotech ETFs By Todd ShriberFebruary 6, 2024
ETF Building Blocks Content Hub How ETF Investors Can Take Advantage of Deal Activity By Roxanna Islam, CFA, CAIAJanuary 18, 2024
Beyond Basic Beta Content Hub What’s Now Inside Some Fundamentally Focused ETFs By Todd RosenbluthJanuary 8, 2024
ETF Building Blocks Content Hub Biotech ETF SBIO’s Momentum Strong to End 2023 By Nick Peters-GoldenDecember 28, 2023
ETF Building Blocks Content Hub Biotech ETF SBIO Sees Buy Signal Amid Hot Returns By Nick Peters-GoldenDecember 14, 2023
